XL765, a dual mTOR and PI3K oral inhibitor, is the first member of this class to be examined in glioblastoma patients; a phase I trial combining radiation therapy (RT)/TMZ with XL765 in patients with recurrent gliomas is under way. The gene discussed is MTOR; the disease is glioblastoma.